Christopher Matheny

Company: Innovent Biologics, Inc.

Job title: Vice President, Clinical Development

Seminars:

Addressing & Mitigating Gastrointestinal Toxicity in Claudin-Targeted Cancer Treatments 12:15 pm

Investigating the gastrointestinal toxicity associated with claudin-targeted therapies, including mechanisms of toxicity and patient case studies Understanding strategies for managing and mitigating GI toxicity, such as dose adjustments, supportive care measures, and novel therapeutic approaches Exploring clinical trial designs aimed at reducing treatment-related GI toxicity, including the use of predictive biomarkers and early intervention strategiesRead more

day: Conference Day 1